FOXO4-DRI Peptide: The Targeted Senolytic That Restores Hair and Fitness
Expert Summary
FOXO4-DRI is a synthetic peptide designed to interfere with the FOXO4-p53 protein-protein interaction that keeps senescent cells alive. FOXO4 (a forkhead box transcription factor) is upregulated in senescent cells and directly binds p53 to sequester it in the nucleus, preventing p53-mediated apoptosis. The DRI peptide competes for this interaction, freeing p53 to trigger apoptosis in senescent cells.
Key Facts
- Mechanism specificity: FOXO4-p53 interaction is specifically elevated in senescent cells vs healthy cells. The DRI peptide's selectivity for senescent cells is arguably higher than BCL-2 family inhibitors, which have some activity in non-senescent cells.
- DRI design: D-amino acid retro-inverso peptides are mirror-image versions of natural peptides — resistant to protease degradation and with potentially longer plasma half-life. This design choice was specifically made for therapeutic application.
- Otte lab results (2017, Cell): In aged BALB/c mice, three biweekly injections of FOXO4-DRI restored hair density (alopecia reversal), restored exercise tolerance, and improved kidney function (creatinine levels). These results generated significant media attention.
- Route of administration: Subcutaneous injection in animal studies. No oral formulation has been validated. The peptide's size (>15 amino acids) limits oral bioavailability.
- Human accessibility issues: No FDA-approved pharmaceutical, no clinical trials registered. Available from research peptide suppliers (for research use only). Self-administration of peptides purchased online carries significant risks of incorrect dosing, contamination, and unknown immunogenicity.
- Future potential: If translated to humans, FOXO4-DRI would represent the most mechanistically specific senolytic to date. Human trials are the next step; as of 2026, none have been registered.
Recommended Products
Frequently Asked Questions
Can I buy FOXO4-DRI for human use?
Research peptide vendors sell FOXO4-DRI for laboratory use only. Self-administration carries risks of contamination (bacterial endotoxins), incorrect dosing, allergic reactions, and unknown long-term effects. It is not approved for human use.
Why haven't FOXO4-DRI human trials started?
Peptide drug development is complex and expensive. FOXO4-DRI requires injectable formulation (no oral bioavailability), immunogenicity testing, and extensive preclinical safety data before human trials. No pharmaceutical company has yet sponsored the required development program.
Scientific References
- Baar MP et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell. 2017. PMID: 28340339